Donepezil 10 mg Tablets Under Fasting Conditions

NCT ID: NCT01439230

Last Updated: 2011-09-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2007-08-31

Brief Summary

The objective of this study was to compare the rate and extent of absorption of donepezil 10 mg tablet (test) versus Aricept® (reference), administered as a 1 x 10 mg tablet under fasting conditions.

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA Bioequivalence Statistical Methods

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

Investigational Test Product

Donepezil 10 mg Tablets

Group Type: EXPERIMENTAL

Donepezil

Intervention Type: DRUG

10 mg Tablet

Reference Listed Drug

Aricept® 10 mg Tablets

Group Type: ACTIVE_COMPARATOR

Aricept®

Intervention Type: DRUG

10 mg Tablet

Interventions

Donepezil

10 mg Tablet

Intervention Type: DRUG

Aricept®

10 mg Tablet

Intervention Type: DRUG

Other Intervention Names

Donepezil (generic name)

Eligibility Criteria

Inclusion Criteria

• Male or female, non-smoker, > 18 and < 55 years of age.
• Capable of consent.
• BMI > 19.0 and < 27.0.
• Good state of health (no clinically significant deviations from normal clinical results and laboratory test findings.

• Clinically significant illnesses (including hyperglycemia, any form of diabetes or glucose intolerance, congestive heart failure, hepatitis, hypotensive episodes) or surgery within 8 weeks prior to dosing.
• Any clinically significant abnormality or abnormal laboratory test results found during medical screening.
• Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the subject from participating in the study.
• Positive test for hepatitis B, hepatitis C, or HIV at screening.
• ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 95 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
• History of significant alcohol abuse or drug abuse within one year prior to screening visit.
• Regular use of alcohol within 12 months prior to the screening visit (more than 14 units of alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]), or positive alcohol breath test as screening.
• Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine, and crack) within 1 year prior to the screening visit or positive drug screen at screening.
• History of allergic reactions to donepezil, piperidine derivatives, or other related drugs.
• Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; examples of inhibitors: antidepressants, cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration of the study medication.
• Use of an investigational drug or participation in an investigational study within 30 days prior to dosing.
• Clinically significant history or presence of any gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
• Any clinically significant history or presence of neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, or metabolic disease.
• Use of prescription medication within 14 days prior to the administration of study medication of over-the-counter products (including natural food supplements, vitamins, garlic as a supplement) within 7 days prior to administration of the study medication, except for topical products without systemic absorption and hormonal contraceptives.
• Difficulty to swallow study medication.
• Use of any tobacco products in the 3 months preceding the screening visit.
• Any food allergy, intolerance, restriction, or special diet that, in the opinion of the Medical Sub-Investigator, could contraindicate the subject's participation in this study.
• A depot injection or an implant of any drug (other than hormonal contraceptives) within 3 months prior to administration of the study medication.
• Donation of plasma (500 mL) within 7 days prior to drug administration. Donation of loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to the administration of the study medication as follows: 50 mL to 499 mL of whole blood within 30 days, or more than 499 mL of whole blood within 56 days prior to drug administration.
• Positive urine pregnancy test at screening.
• Breast-feeding subject.
• Female subjects of childbearing potential having unprotected sexual intercourse with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy for at least 6 months) within 14 days prior to study drug administration.
• History of asthma or obstructive pulmonary disease.
• History of ulcer disease.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Teva Pharmaceuticals USA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Benoit J Deschamps, M.D.

Role: PRINCIPAL_INVESTIGATOR

Anapharm

Locations

Anapharm

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

70185

Identifier Type: -

Identifier Source: org_study_id